[HTML][HTML] Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: a retrospective cohort study
C Weng, X Wang, L Huang, X Lin, Q Liu - Plos one, 2021 - journals.plos.org
Introduction Patients at intermediate-high risk of developing a pulmonary embolism (PE) are
very likely to experience adverse outcomes, such as cardiovascular instability and death …
very likely to experience adverse outcomes, such as cardiovascular instability and death …
[HTML][HTML] Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study
C Weng, X Wang, L Huang, X Lin, Q Liu - PLoS ONE, 2021 - ncbi.nlm.nih.gov
Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk
pulmonary embolism: A retrospective cohort study - PMC Back to Top Skip to main content NIH …
pulmonary embolism: A retrospective cohort study - PMC Back to Top Skip to main content NIH …
Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study.
C Weng, X Wang, L Huang, X Lin, Q Liu - PLoS ONE, 2021 - search.ebscohost.com
Introduction: Patients at intermediate-high risk of developing a pulmonary embolism (PE) are
very likely to experience adverse outcomes, such as cardiovascular instability and death …
very likely to experience adverse outcomes, such as cardiovascular instability and death …
Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study.
C Weng, X Wang, L Huang, X Lin, Q Liu - PLoS ONE, 2021 - go.gale.com
Introduction Patients at intermediate-high risk of developing a pulmonary embolism (PE) are
very likely to experience adverse outcomes, such as cardiovascular instability and death …
very likely to experience adverse outcomes, such as cardiovascular instability and death …
Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study.
C Weng, X Wang, L Huang, X Lin, Q Liu - Plos one, 2021 - europepmc.org
Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk
pulmonary embolism: A retrospective cohort study. - Abstract - Europe PMC Sign in | Create …
pulmonary embolism: A retrospective cohort study. - Abstract - Europe PMC Sign in | Create …
[引用][C] Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study
C Weng, X Wang, L Huang, X Lin, Q Liu - PLoS ONE, 2021 - ui.adsabs.harvard.edu
Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk
pulmonary embolism: A retrospective cohort study - NASA/ADS Now on home page ads icon …
pulmonary embolism: A retrospective cohort study - NASA/ADS Now on home page ads icon …
[PDF][PDF] Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study
C Weng, X Wang, L Huang, X Lin, Q Liu - PLoS ONE, 2021 - scholar.archive.org
Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk
pulmonary embolism: A retrospective cohor Page 1 RESEARCH ARTICLE Low-dose urokinase …
pulmonary embolism: A retrospective cohor Page 1 RESEARCH ARTICLE Low-dose urokinase …
Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study
C Weng, X Wang, L Huang, X Lin, Q Liu - PloS one, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction Patients at intermediate-high risk of developing a pulmonary embolism (PE) are
very likely to experience adverse outcomes, such as cardiovascular instability and death …
very likely to experience adverse outcomes, such as cardiovascular instability and death …